Below is a comprehensive archive of press releases from MSF-USA. Use the options in the boxes below to filter results based on your preferences.

May 27, 2016

NEW YORK/ISE-SHIMA, JAPAN, MAY 27, 2016—While G7 leaders acknowledged during their summit this week that the current system of research and development is failing to deliver innovation and affordable access to medicines and vaccines for people around the world, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is disappointed that the solutions proposed by the G7 will not address these failures head-on.

MSF issued the following statement from Jeremie Bodin, general director of MSF Japan:

May 26, 2016

New York/Ise-Shima/Geneva—As the leaders of the G7 countries gather in Ise-Shima, Japan over the next two days, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is urging them to make a bold commitment to prioritize a better global response to public health emergencies and to take action to encourage the research and development (R&D) and affordable pricing of critical medicines.

May 19, 2016

The O’Neill Report is the British Government’s response to tackling the emerging antibiotic resistance crisis. In order to overcome this global threat, all countries must play their part and take action to address the crisis, including funding research and development for new tools—new classes of antibiotics, but also diagnostics and vaccines—while ensuring sustainable and affordable access for those new tools. At the same time, steps need to be taken to conserve existing antibiotics for as long as possible.

May 10, 2016

Gilead Sciences has been seeking patents in India for the hepatitis C drug sofosbuvir. The patent applications have been challenged by groups of people living with hepatitis C and HIV through "pre-grant oppositions." The patent just granted by India’s patent office was initially rejected in January 2015, just before President Obama’s visit to India, which was seen as vexing the US. Gilead appealed the rejection and the patent has now been granted.

April 21, 2016

In advance of the next round of the Regional Comprehensive Economic Partnership (RCEP) negotiations starting in Perth, Australia, this Sunday, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is warning that current proposals in this trade agreement could severely restrict access to affordable medicines for millions of people around the world. Text from a leaked chapter on intellectual property shows that Japan and South Korea have made proposals that go beyond what international trade rules require, undermining access to affordable generic medicines and making it harder for patients and treatment providers like MSF to access affordable, lifesaving medicines.

April 12, 2016

More than fifty groups have come together to demand that the US Congress reject the Trans-Pacific Partnership Trade Deal (TPP) due to provisions it contains that would undermine public health. In a letter sent to Congress today, the groups outlined the damaging effects the trade deal would have on public health, and said lawmakers should not vote for the TPP unless damaging provisions are removed.

March 11, 2016

New York/New Delhi—Doctors Without Borders/Médecins Sans Frontières (MSF) has filed a "patent opposition" in India to block US pharmaceutical company Pfizer from patenting a pneumococcal conjugate vaccine, and ensure affordable access to this critical vaccine (PCV13). This is the first time a vaccine (biosimilar) patent has been challenged in India by a medical organization and, if successful, will make affordable versions of this lifesaving vaccine available to developing countries and humanitarian organizations.

March 10, 2016

Judit Rius Sanjuan, Access Campaign manager & legal policy advisor at Doctors Without Borders/Médecins Sans Frontières (MSF), made the following statement after KaloBios Pharmaceuticals obtained bankruptcy court permission to keep pursing a drug that could receive a US Federal Drug Administration Priority Review Voucher (PRV).

March 09, 2016

New York— A Senate committee voted today to add Zika to the list of diseases eligible for the US Federal Drug Administration (FDA) Priority Review Voucher (PRV) program for neglected diseases, but did not fix major loopholes that make the PRV program for neglected diseases ripe for abuse by pharmaceutical companies.

February 26, 2016

New York/New Delhi—In proceedings that could have major implications for millions of people waiting for affordable access to a lifesaving hepatitis C drug, the Indian Patent Office this week began hearings to determine whether US pharmaceutical company Gilead Sciences deserves a patent for sofosbuvir, a hepatitis C drug for which the company currently charges $1,000 per pill in the US.

Pages